Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study.
CONCLUSIONS: The AL safety profile over 180 weeks (3.5 years) of follow-up was consistent with prior 52-week results. Continued therapeutic efficacy, based on PANSST and CGI-S scores, was observed throughout the post hoc analysis period.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01626456; ClinicalTrials.gov identifier: NCT01895452.
PMID: 32841554 [PubMed - in process]
Source: Journal of Clinical Psychiatry - Category: Psychiatry Tags: J Clin Psychiatry Source Type: research